Update: A first glimpse of MOR202's potential
Preliminary data from the Phase I/II study in multiple myeloma (MM) with MOR202 were promising and support our view that Celgene returned the rights to the antibody for strategic reasons. It is too soon to make meaningful comparisons to the other CD38 antibodies in development, but that should start to become possible when more data are presented at ASH. There were also more Phase II data with MOR208 presented at ASCO, which further confirmed its potential in non-Hodgkin's lymphoma (NHL).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.